Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple Myeloma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Cormier, Françoise ^a,b,c   Monjanel, Hélène ^a,b,c,d   Fabre, Claire ^e   Billot, Katy ^a,b,c   Sapharikas, Elène ^a,b,c   Chereau, Fanny ^a,b,c   Bordereaux, Didier ^a,b,c   Molina, Thierry J ^f   Avet Loiseau, Hervé ^g,h   Baud, Véronique ^a,b,c  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e INSTITUT CURIE   (France)

^f HÔTEL DIEU   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNDECAN 1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CIAP2 GENE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEMBRANE POTENTIAL; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL SURVIVAL; DNA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SYNDECAN-1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TRANSCRIPTION, GENETIC;

EID: 84875494291     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059127     Document Type: Article

References (50)

1. Palumbo A, Anderson K, (2011) Multiple myeloma. N Engl J Med 364: 1046-1060.
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC, (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598.
3. Laubach J, Richardson P, Anderson K, (2011) Multiple myeloma. Annu Rev Med 62: 249-264.
4. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, et al. (2012) Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 9: 135-143.
5. Hideshima T, Anderson KC, (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937.
6. Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR, (2008) NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 15: 391-399.
7. Staudt LM, (2010) Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2: a000109.
8. Baud V, Karin M, (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40.
9. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, et al. (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103: 3175-3184.
10. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647.
11. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, et al. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 87: 1104-1112.
12. Landowski TH, Olashaw NE, Agrawal D, Dalton WS, (2003) Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 22: 2417-2421.
13. Gilmore TD, Wolenski FS, (2012) NF-kappaB: where did it come from and why? Immunol Rev 246: 14-35.
14. Hayden MS, Ghosh S, (2012) NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26: 203-234.
15. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, et al. (1995) Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80: 331-340.
16. Weih F, Warr G, Yang H, Bravo R, (1997) Multifocal defects in immune responses in RelB-deficient mice. J Immunol 158: 5211-5218.
17. Weih DS, Yilmaz ZB, Weih F, (2001) Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines. J Immunol 167: 1909-1919.
18. Hailfinger S, Nogai H, Pelzer C, Jaworski M, Cabalzar K, et al. (2011) Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci U S A 108: 14596-14601.
19. Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, et al. (2007) Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 21: 1521-1531.
20. Sun SC, (2012) The noncanonical NF-kappaB pathway. Immunol Rev 246: 125-140.
21. Dejardin E, (2006) The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 72: 1161-1179.
22. Marienfeld R, May MJ, Berberich I, Serfling E, Ghosh S, et al. (2003) RelB forms transcriptionally inactive complexes with RelA/p65. J Biol Chem 278: 19852-19860.
23. Jacque E, Tchenio T, Piton G, Romeo PH, Baud V, (2005) RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. Proc Natl Acad Sci U S A 102: 14635-14640.
24. Yilmaz ZB, Weih DS, Sivakumar V, Weih F, (2003) RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. Embo J 22: 121-130.
25. Derudder E, Dejardin E, Pritchard LL, Green DR, Korner M, et al. (2003) RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. J Biol Chem 278: 23278-23284.
26. Maier HJ, Marienfeld R, Wirth T, Baumann B, (2003) Critical role of RelB serine 368 for dimerization and p100 stabilization. J Biol Chem 278: 39242-39250.
27. Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, et al. (2004) Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB: p52 dimers. Embo J 23: 4202-4210.
28. Fusco AJ, Huang DB, Miller D, Wang VY, Vu D, et al. (2009) NF-kappaB p52: RelB heterodimer recognizes two classes of kappaB sites with two distinct modes. EMBO Rep 10: 152-159.
29. Natoli G, De Santa F, (2006) Shaping alternative NF-kappaB-dependent gene expression programs: new clues to specificity. Cell Death Differ 13: 693-696.
30. Saccani S, Pantano S, Natoli G, (2003) Modulation of NF-kappaB activity by exchange of dimers. Mol Cell 11: 1563-1574.
31. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144.
32. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, et al. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.
33. Kieusseian A, Chagraoui J, Kerdudo C, Mangeot PE, Gage PJ, et al. (2006) Expression of Pitx2 in stromal cells is required for normal hematopoiesis. Blood 107: 492-500.
34. Jacque E, Billot K, Authier H, Bordereaux D, Baud V (2012) RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation. Oncogene Jul 9. Epub ahead of print. doi:10.1038/onc.2012.282.
35. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, et al. (2008) Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 6: 1356-1364.
36. Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, et al. (2009) Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 113: 5228-5236.
37. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, et al. (2010) Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115: 3541-3552.
38. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
39. Basseres DS, Baldwin AS, (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830.
40. Jost PJ, Ruland J, (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109: 2700-2707.
41. Naugler WE, Karin M, (2008) NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18: 19-26.
42. Perkins ND, (2012) The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 12: 121-132.
43. Smale ST, (2012) Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors. Immunol Rev 246: 193-204.
44. Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, et al. (2012) Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 14: 375-385.
45. Karin M, Greten FR, (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759.
46. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, et al. (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66: 6675-6682.
47. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr, (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683.
48. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, et al. (2008) Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 9: 1364-1370.
49. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, et al. (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131: 669-681.
50. Schwarzer R, Dorken B, Jundt F, (2012) Notch is an essential upstream regulator of NF-kappaB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 26: 806-813.